Enanta Pharmaceuticals (NASDAQ:ENTA) Raised to “Hold” at Wall Street Zen

Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also commented on ENTA. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a research note on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $12.96 on Friday. The firm’s fifty day simple moving average is $13.13 and its 200-day simple moving average is $13.29. The stock has a market cap of $377.40 million, a PE ratio of -5.38 and a beta of 0.96. Enanta Pharmaceuticals has a fifty-two week low of $10.12 and a fifty-two week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The company had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Equities analysts anticipate that Enanta Pharmaceuticals will post -2.36 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

Large investors have recently modified their holdings of the business. Quantinno Capital Management LP increased its position in Enanta Pharmaceuticals by 4.9% during the first quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock worth $444,000 after buying an additional 1,627 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at $36,000. Legal & General Group Plc purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at $41,000. Clearstead Trust LLC acquired a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at $74,000. Finally, Wellington Management Group LLP boosted its stake in shares of Enanta Pharmaceuticals by 8.9% during the second quarter. Wellington Management Group LLP now owns 81,633 shares of the biotechnology company’s stock valued at $1,190,000 after acquiring an additional 6,673 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.

Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection.